netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Bevacizumab found 18 matches

Formulary items 6 matches
Sub Section Title / notes 1 match
   
Open monograph to display formulary status BNF Category
  Bevacizumab  (Avastin®) Malignant disease and immunosuppression - Bevacizumab - 08.01.05
  Bevacizumab 1.25mg/0.05ml intravitreal injection Eye - Subfoveal choroidal neovascularisation - 11.08.02
  Bevacizumab gamma  (Lytenava®) Eye - Subfoveal choroidal neovascularisation - 11.08.02
  Cytotoxic Drug Atezolizumab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Olaparib  (Lynparza®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Pembrolizumab  (Keytruda®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (08.01.05)
link in drug section MHRA Drug Safety Update (January 2011): Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (08.01.05)
link in drug section NICE TA1008 : Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (08.01.03)
link in drug section NICE TA1022: Bevacizumab gamma for treating wet age-related macular degeneration (11.08.02)
link in drug section NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (08.01.05)
link in drug section NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (08.01.05)
link in drug section NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (08.01.05)
link in drug section NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (08.01.05)
link in drug section NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (08.01.05)
link in drug section TA1136: Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (08.01.05)

SubSection Titles / notes  
Bevacizumab - (08.01.05)

 
netFormulary